ArticleAsian journal of transfusion science
Hepatitis E virus seroprevalence and awareness about feco-oral transmission in blood donors at a single center in Puducherry.
Article in Asian journal of transfusion science. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluating the economic viability of hepatitis E virus serological screening among blood donors: A prospective study from India for advancing blood safety.Asian journal of transfusion scienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAsymptomatic hepatitis E virus (HEV) infections have been found in blood donors. Posttransfusion hepatitis E has been reported and raises concern due to cases of HEV-related mortality in patients with underlying cirrhosis or immunocompromised patients. This study aimed to determine the seroprevalence of HEV-associated sociodemographic parameters, awareness about feco-oral transmitted diseases among healthy blood donors attending a tertiary care teaching hospital blood center. MATERIALS AND
methodsThis was a cross-sectional study done for 1 year from January 2019 to January 2020. Our study included a sample size of 920 blood donors attending for donation at a single center. All the samples were tested using HEV IgM kit with the antigen used for coating were four synthetic peptides with conservative epitopes of ORF2 and ORF3 in genotypes 1, 2, 3, and 4. An open-ended questionnaire regarding awareness of the feco-oral transmission of diseases was administered; data regarding clinical, epidemiological, and demographic characteristics were collected from the donors by a structured data collection proforma. The responses were recorded.
resultsOur study results showed a seroprevalence of 1.41%. All the reactive donors were asymptomatic during our routine screening procedures. Most of the donors (457 donors), i.e., 49.7%, belonged to the lower middle class; the mean age of the study population was 28.6 years (standard deviation 8.9).
conclusionThis study reflects the burden of HEV in the local population, and this result can be considered a preliminary step in quantifying the risk of transfusion-transmitted HEV. Cost-effectiveness in implementing HEV screening as a part of routine TTI screening to be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.